Cargando…
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
The aim of this study was to evaluate the cost-effectiveness of Anbainuo (ABN) plus methotrexate (MTX) (ABN + MTX) versus conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients. Forty-eight moderate to severe RA patients underwent ABN + MTX or cDMARDs tre...
Autores principales: | Tian, Feng, Li, Jing-Yang, Wen, Zhen-Hua, Luo, Xiao-Wen, Deng, Li, Zhang, Liang, He, Jing-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890288/ https://www.ncbi.nlm.nih.gov/pubmed/31770193 http://dx.doi.org/10.1097/MD.0000000000017750 |
Ejemplares similares
-
Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients
por: Shi, Zhi-Chao, et al.
Publicado: (2020) -
Cost-effectiveness of Anbainuo plus methotrexate compared to conventional disease-modifying antirheumatic drugs for rheumatoid arthritis patients in China
por: Tian, Feng, et al.
Publicado: (2021) -
Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015) -
Favorable retention rates and safety of conventional anti-rheumatic drugs in older patients with rheumatoid arthritis
por: Alpay-Kanitez, Nilüfer, et al.
Publicado: (2020) -
Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor
por: Lan, Joung-Liang, et al.
Publicado: (2017)